扶正化积汤治疗非小细胞肺癌的分子机制：基于网络药理学及体外实验验证

打开文本图片集

Abstract：ObjectiveToinvestigatetheinibitoryeffctofFuzengHuajiDecoctionagainstnon-smallcellungcancer（NCLC） cellsin vitroandexploretheunderlyingmechanism.MethodsTheactiveingredientsandtargetsofFuzhengHuaji Decoction wereidentifiedusingTCMSPand SwissTargetPredictiondatabases.NSCLC-related targets from GeneCardsand PharmGKB wereintersectedithergetsofteDecoctionnaprotei-proteininteractin（P）etorkwasonstructedtoetify the core targets，which were analyzed with GO and KEGG pathway enrichment analysis. Cultured A549 cels were treated withdiffrentoncentrationsofFuzhengHuajiDcoction-medicatedserumandtheangesincellproliferationaotosis， and protein expressions were examiedusingCCK-8assayannexinV-TC/PIstainingand Westernbloting.Results Fuzheng Huaji Decoctioncontained140active ingredients，and707 drug-disease intersecting targets were identified.Among these targets，TP53，AK1，A，H，AB，GFR，ndredenidateoretargeswcheeoe inthebiologicalrocseelatedtiasdcetosde-AasdAPKaha.lulr dockingstudiesidicatedstrongindingaityofteactiveinredietswith53AKT，adHFA.InuuredA49cels treatment with 2.5% 5% and 10% Fuzheng Huaji Decoction-medicated serum significantly inhibited cell proliferation， promotedcellposisdowegulaedeexpressiovelsof，-A08）nd53proteins.Coui FuzhengHuajiDecoctioninhibitsproliferationofNSCLCcellspossblybydownregulatingtheexpressionsofHF1A，p-AKT （Thr308）， and TP53.

Keywords：Fuzheng HuajiDecoction;non-smallcelllungcancer;network pharmacology;moleculardocking;invitro experiments

肺癌作为死亡率最高的恶性肿瘤之一，已成为全球性的健康问题1。（剩余14742字）